Introduction
Natural products from plants or Chinese herbs have been used as traditional remedies in Asian countries for hundreds of years. The development of compounds with antitumor effects from natural products has become a very important topic. Flavonoids are commonly found in most plants and exert a remarkable spectrum of biological activities that affect basic cell functions, and several beneficial biological activities of flavonoids including antioxidant, antitumor, and anti-inflammation properties have been identified in several studies [1, 2] . Flavonoids are also dietary pharmacological agents, which may block neoplastic inception or delay disease progression [3, 4] . These data indicate that certain flavonoids may be used as possible chemopreventive or chemotherapeutic agents.
The great prevalence of flavonoids in the vegetal kingdom act, not only as the colored pigments of flowers, but also as enzyme inhibitors, precursors of toxic substance, and a defense against ultraviolet radiation exposure. Flavonoids were found to act on the growth of cancer cells, which means that it possesses potential anti-tumor activity. For example, baicalein, epigallocatechin (EGC) gallate and green tea extract were reported to inhibit tumor growth [5] [6] [7] . Furthermore, epidemiological studies indicated that diets containing linseed and soy (rich in isoflavonoids and lignans) might protect against colon, breast, and prostate cancer [8] . Flavonoids are benso-r-pirone derivatives that can be grouped according to the presence of different substituents on the rings and to the degree of benso-r-pirone ring saturation. Artonin B is a prenylflavonoid that is obtained from the root bark of Artocarpus heterophyllus Lamk [9] . Artonin B is a derivative from heterophyllin and possesses the structure in C-10 position of isoprenoid moiety. However, the effects of artonin B on cancer cell growth have rarely been investigated in great detail.
Apoptosis is a cell suicide program, which is essential for the development and maintenance of tissue homeostasis and the elimination of unwanted or damaged cells from multicellular organisms [10, 11] . Apoptosis is characterized by a series of morphological changes involving cell shrinkage, chromatin condensation and the formation of apoptotic bodies [12] . It can be triggered by various extracellular and intracellular stimuli that result in the coordinated activation of family proteases called caspases. The activation of caspase 3 pathways is an important downstream executioner in apoptosis [13] . Human leukemia is a commonly diagnosed neoplasm and the major leading cause of human death. CCRF-CEM cells are acute lymphoblastic leukemia (ALL) cells. ALL represents the clonal proliferation of malignantly transformed lymphoid progenitors in the bone marrow. The treatment of patients with recurrent cancer is usually unsuccessful, and the development of new potent treatments has become the focal point for cancer treatment. Therefore, we evaluated the effects and action mechanism of artonin B on human acute lymphoblastic leukemia CCRF-CEM cells. In this present study, the cell cytotoxicity of four prenylflavonoid compounds was examined. Furthermore, morphological nuclear fragmentation, apoptotic body formation, the change of mitochondrial membrane potential, cytochrome c release, cell cycle change, Bcl-2, Bax, and Bak protein expression, and caspase 3 activity in artonin B treated human CCRF-CEM leukemia cells were investigated.
Materials and methods
Materials RPMI-1640, fetal bovine serum (FBS), and antibiotics were purchased from Hyclone. Caspase 3 assays kits and caspase 3 inhibitor (z-DEVD-fmk) were obtained from Biovision. The cytochrome c was purchased from R&D Systems. Monoclonal antibodies of Bcl-2, Bax, Bak, and anti-rabbit IgGs were obtained from Cell Signaling. Hoechst 33258 and the rest of chemicals were purchased from Sigma.
The four prenylflavonoid compounds that were extracted from Artocarpus species (Moraceae) were obtained from Dr Chun-nan LIN (School of Pharmacy, Kaohsiung Medical University, Taiwan, China). Artocarpanone ( Figure 1A ) was an isoprenoid-flavone [14] . Artonin A and artonin B ( Figure  1B and 1C) were extracted from the root bark of Artocarpus heterophyllus Lamk (9) . And, the new prenylflavonoidArtocammunols CE ( Figure 1D ) was obtained from the Artocarpus communis [15] . These four prenylflavonoid compounds were dissolved in dimethyl sulfoxide (DMSO) as stock solution. The final concentration of DMSO in each experiment was less than 0.1%.
Cell culture
Human acute lymphoblastic leukemia cell line (CCRF-CEM) was purchased from the Culture Collection and Research Center (Taiwan ). CCRF-CEM cells were maintained in RPMI-1640 medium (Hyclone) supplemented with 10% heat-inactivated fetal bovine serum (Hyclone), 100 µg/mL penicillin, 100 µg/mL streptomycin and 100 µg/mL amphotericin B (Hyclone). The cells were grown in a humidified incubator at 37 ºC under a 5% CO 2 /95% air atmosphere. For each experiment, 3×10 5 cells were seeded in each well in a 24-well plate containing 1 mL of fresh medium and incubated with or without chemical treatment for the indicated time. For toxicity study, the cells were treated with drugs during the exponential phase of cell growth.
Cytotoxicity assay The cytotoxic effect of drugs was determined using the MTT method [16] . In brief, 100 µL MTT solution (0.5 mg/mL in phosphate-buffer saline or PBS) was added to each well at the end of each experiment. After 1-2 h incubation at 37 ºC, 10 µL Triton X-100 (10%) was added and mixed well. Once the cells were completely dissolved, the absorbance difference at 550 nm was measured using a Assay of mitochondrial membrane potential Initially, 1×10 6 human CCRF-CEM cells/mL were incubated with 2 mmol/L rhodamine 123 for 10 min at 37 °C. After the incorporation of a fluorescent probe, the cells were incubated for up to 4 h with or without 10 µmol/L artonin B. At the end of incubation, the cells were washed twice with PBS, harvested by centrifugation, and then resuspended in 1.5 mL PBS. The fluorescent intensity of each cell suspension was measured at an excitation wavelength 480 nm and an emission wavelength 530 nm in a Perkin-Elmer Victor 3 fluorescent microplate reader. The fluorescence intensity was used as an arbitrary unit representing the mitochondrial transmembrane potential.
Cytochrome c release Human CCRF-CEM cells were seeded in 2 mL fresh medium at an initial density of 1×10 6 cells/mL and incubated for up to 4 h with or without 10 µmol/ L artonin B. After the incubation, the cells were harvested by centrifugation and washed twice with PBS. The cells were suspended in 200 mL lysis buffer (195 mmol/L mannitol; 65 mmol/L sucrose; 2 mmol/L HEPES, pH 7.4; 0.05 mmol/L EGTA; 0.01 mmol/L MgCl 2 ; 0.5 g/mL BSA) and lysed by the addition of 0.01% digitonin. The cytosolic fraction was obtained from 10 000×g centrifugation for 10 min and was collected for cyt c assay in 1×RD5P calibrator diluent (cytochrome c Immunoassay Kit; R&D Systems, MN, USA). After reacting with cyt c antibody and substrate, the absorbance was measured at 450 nm (reference wavelength is 540 nm).
Western blot analysis After being exposed to the indicated concentration of artonin B, human CCRF-CEM cells were washed with cold PBS. Whole cell extracts were prepared by incubating the cells with cold lysis buffer (20 mmol/L Tris-HCl; pH 7.5, 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1% Triton, 2.5 mmol/L sodium pyrophosphate, 1 mmol/L β-glycerophosphate, 1 mmol/L Na 3 VO 4 , 1 mg/mL leupeptin, and 1 mmol/L PMSF). The protein content of the lysates was determined using the DC protein assay kit (Bio-Rad). The cell lysates (25 µg protein/lane) were electro-phoresized on 12% SDS-polyacrylamide gels. The cellular proteins were then transferred to PVDF membranes by electroblotting for 2 h and Western blot analysis was carried out as previously described [17] . The protein levels were visualized with an enhanced chemiluminescence detection kit (Amersham).
Preparation of cytosolic extract and measurement of caspase 3 activity After the treatment with indicated agents, cells were harvested and washed with PBS by centrifugation at 750× g for 5 min at 4 ºC. The cell pellets were resuspended in lysis buffer (caspase colorimetric assay kits; Biovision) and left on ice for 30 min. The lysates were centrifuged at 10 000×g for 10 min and the supernatant (20 µL) was used for caspase-3 activity assay in the lysis buffer containing DEVDpNA, a specific substrate to caspase-3. The concentration of pNA, as the product from enzymatic converting of DEVDpNA by caspase-3, was measured at 405 nm and used as an indication of caspase-3 activity.
Assessment of cell necrosis The necrotic cell death was measured by the release of lactate dehydrogenase (LDH) into the culture medium, which indicates the loss of membrane integrity and cell necrosis. LDH activity was measured using a commercial assay kit (Cytotoxicity assay kit, Promega), where the released LDH in culture supernatants is measured with a coupled enzymatic assay, which results in the conversion of a tetrazolium salt into a red formazan product. The necrotic percentage was expressed as (sample value/maximal release)×100%, where the maximal release was obtained following the treatment of control cells with 0.5% Triton X-100 for 10 min at room temperature.
Statistic analysis For each experiment involving assessment of cell survival, apoptotic cell, and caspase-3 activity are presented as the mean and standard error (SEM) for four to five experiments. The statistical analysis of data was performed by one-way ANOVA, followed by the Schefft test, and P-values less than 0.05 were considered significant.
Results
Effects of prenylflavonoid compounds on cytotoxicity in human CCRF-CEM leukemia cells The cytotoxic effects of four prenylflavonoid compounds were examined in human CCRF-CEM leukemia cells. When CCRF-CEM leukemia cells were incubated with 10 µmol/L of four prenylflavonoids, the data showed that artonin B had a more potent cytotoxicity than the other compounds ( Figure 2 ). In addition, the cell survival rate decreased in a dose-dependent manner ( Figure  3A) . Under the same treatment, artonin B did not cause any cell loss in HaCa cells ( Figure 3B ). Artonin B elicited a significant decrease of cell survival rate in human CCRF-CEM leukemia cells, which also exhibited a time-dependent manner (Figure 4) . After an exposure time of 6 h, the cytotoxic effects were noticed at a concentration of 5 µmol/L and 10 µmol/L of artonin B, with a the survival rate decreasing to 64% at 5 µmol/L and 22% at 10 µmol/L. Accordingly, after 24 h exposure cytotoxic effects started to become apparent at a concentration of approximately 3-10 µmol/L, cell viability declined considerably at 3 µmol/L and was approximately 10% at 10 µmol/L of artonin B ( Figure 4) . The IC 50 value of artonin B was 3.45±0.50 µmol/L.
Assessment of artonin B-induced cell apoptosis and intracellular events
To determine whether the artonin Binduced cytotoxicity was to undergo the apoptotic cell pathway, human CCRF-CEM leukemia cells were incubated in presence of 1-10 µmol/L artonin B for 24 h. The morphological examination reveled that artonin B-treated cells showed typical apoptotic morphological changes, such as cell shrinkage, nuclear fragmentation, and apoptotic body formation ( Figure 5 ). Artonin B-treatment significantly increased the number of cells with apoptotic body formation ( Figure 5D,5E ), while the control cells and 1-3 µmol/L of artonin B-treated cells showed seldom apoptotic body formation ( Figure 5A-5C ). The number of apoptotic cells, which carry fragmented nuclear particles, were significantly increased in artonin B-treated cells in a dose-dependent manner ( Figure 5F ).
The necrotic indication of cellular lactate dehydrogenase (LDH) release was also examined after artonin B treatment ( Figure 6 ). The data showed that 5 µmol/L and 10 µmol/L artonin B induced an increase of LDH release in only 20.59%±2.12% and 28.23%±0.81%, respectively, while the cell survival rates were 35.33%±0.9% and 14.76%±3.56%, respectively. These data indicated necrotic cytotoxicity was less involved in artonin B action. Thus, artonin B induces leukemia cell death employing an apoptotic pathway.
Cell cycle analysis Figure 7 illustrates the changes of DNA content distribution treated with artonin B 0, 1, 5, or 10 µmol/L for 24 h. We examined these cells for DNA degradation characteristic of apoptosis, indicated by hypoploid DNA content using hypotonic PI staining. Exposure of human CCRF-CEM leukemia cells to 1 µmol/L artonin B promoted approximately the same percentage of hypoploid cells ob- served in the DMSO treated control. As the treatment dose increased the percentage of cells in the hypoploid (sub-G 1 ) phase increased accordingly. Treated with 5 or 10 µmol/L artonin B for 24 h, the rate of sub-G 1 phase cells were increased by 11.43% or 18.56%, respectively.
Changes of mitochondrial membrane potential and release of cytochrome c from mitochondria In the present study, the mitochondrial membrane potential and cytochrome c release were analyzed spectrophotometrically. As shown in Figure 8 , artonin B-induced a time-dependent mitochondrial transmembrane depolarization, represented as the decrease of mitochondrial membrane potential ( Figure 8A ). Concomitantly, a time-dependent artonin B-induced cytochrome c release was also observed in human leukemia CCRF-CEM cells, representing a significant increase of cytosolic cytochrome c concentration ( Figure 8B ). These data suggest that loss of mitochondrial membrane potential may be required for artonin B-induced cytochrome c release into cytosol, that later triggered the cleavage and activation of mitochondrial downstream caspases and onset of apoptosis.
Regulation of Bcl-2 family proteins in artonin B-treated human leukemia CCRF-CEM cells To determine whether Bcl-2 family proteins were modulated in artonin B-induced apoptosis in human leukemia CCRF-CEM cells, the expression of several members of Bcl-2 family proteins was examined by Western blot analysis. As shown in Figure 9 , the exposure of human leukemia CCRF-CEM cells to 1-10 µmol/L artonin B resulted in a marked decrease of Bcl-2 protein expression, but a drastic increase of Bax and Bak protein expression.
Determination of the involvement of caspase 3 activation Artonin B-induced nuclear fragmentation may thus be an apoptotic event provoked along with endonuclease activation via caspase 3 protein. We also examined the caspase 3 activity under the 1-10 µmol/L artonin B treatment. The present study has demonstrated that artonin B treatment increased caspase 3 activities in human CCRF-CEM leukemia cells in a dose-dependent manner (Figure 10 ). Human leukemia CCRF-CEM cells were pretreated with 50 µmol/L caspase 3 inhibitor (z-DEVD-fmk) for 2 h, and then induced to undergo apoptosis by treatment with artonin B. The results clearly showed that the administration of caspase 3 inhibitor alone did not affect the caspase 3 activation, apoptotic cell formation, and cell viability (Figure 11 ). However, z-DEVD-fmk (a specific caspase 3 inhibitor) significantly inhibited artonin B-induced caspase 3 activation, apoptotic cells formation, and cell death in human acute lymphoblastic leukemia cells. 
Discussion
In the present work, we demonstrated that artonin B, one of prenylflavonoids, strongly inhibited the growth of human acute lymphoblastic leukemia CCRF-CEM cells, whereas artonin A, artocarpanone, and artocammunols prenylflavonoid compounds had no effect on the growth of CCRF-CEM cells. This is a pioneer study of artonin B-induced cell cytotoxicity in human leukemia CCRF-CEM cells. Prenylflavonoids exist extensively in plants; however, the structureactivity relationship of their effect is still unknown. These results indicate that heterophyllin structure would be needed in the growth inhibitory effect of prenylflavonoid compounds. Importantly, we observed that artonin B had no effect on the growth of HaCa cells; this is in agreement with data showing that artonin B had a growth inhibitory effect on cancer cells, but not on normal cells. Therefore, artonin B could be a good candidate for acute lymphoblastic leukemia cells therapy without toxicity for normal cells.
Our results revealed that human CCRF-CEM cells treated with artonin B exhibited characteristic morphological features of apoptosis, such as membrane shrinkage chromosomal condensation. The notion that artonin-B treated cells undergo apoptosis rather than necrosis is further supported by the results from cell cycle analysis. The proportion of hypoploid cells (sub-G 1 ) was dramatically increased after artonin-B treatment. These results support the finding that artonin-B induces cell death through apoptotic pathway.
The several mechanisms of activation of apoptosis in different physiological or pathological conditions in cells have been proposed and studied intensively [18] . Numerous factors, such as cytosolic cytochrome c release, the expression of Bcl-2 family proteins, and caspase 3 activation have been suggested to play an essential role in the apoptotic process in cancer cells. Our study demonstrated that a progressive decrease of the mitochondrial membrane potential and release of cytochrome c into the cytosol were observed in artonin-B treated human CCRF-CEM leukemia cells. It has been noticed in many in vitro systems that apoptosis was associated with a loss of mitochondrial membrane potential, which may correspond to the opening of an outer membrane permeability transition pore. Thus, this event has been suggested to be responsible for cytochrome c release into cytosol from mitochondria [19] . In our present study, the cytosolic cytochrome c accumulation in artonin B-induced human CCRF-CEM cells is probably the consequence of the loss of mitochondrial membrane potential, which finally leads to cell death.
The Bcl-2 family is composed of a number of genes that play critical roles in the control of mitochondrial integrity. Several studies have shown that overexpression of Bcl-2 prevents the mitochondrial release of cytochrome c, thereby inhibiting the activation of caspases cascade and apoptosis [20] [21] [22] [23] . In the present study, artonin B-induced apoptosis in human CCRF-CEM leukemia cells was accompanied by upregulation of Bax and Bak and downregulation of Bcl-2. Other studies have demonstrated that Bcl-2, Bax, and Bak can act as channel proteins within the mitochondrial membrane [21, 24, 25] . It is conceivable that the channel property of Bax and Bak may control the mitochondrial permeability transition and other early mitochondrial perturbation. Thus, Bax and Bak may facilitate the passage of some important proteins, such as cytochrome c or other apoptosis-inducing factors that trigger the activation of caspases cascade and apoptosis. Previous reports have also documented that the ratio of pro-and anti-apoptotic proteins determines, at least in part, the susceptibility of cells to a death signal [21, 26, 27] . Our results showed that expression of Bcl-2 family proteins Bcl-2, Bax, and Bak can be regulated differently by artonin B, suggesting that the artonin B-induced apoptosis is controlled by a balanced expression between those apoptosisinducing and apoptosis-suppressing molecules.
Apoptosis is a type of cell death, and agents with the ability to induce apoptosis in tumors have the potential to be used for antitumor therapy. The apoptotic mechanism has been extensively studied, and activation of caspase 3 has been shown to occur in the common apoptotic pathway [28] . The activation of caspases plays a pivotal role in the execution of cell apoptosis [29] . Recent studies have demonstrated that the caspase 3 is a major caspase, which is activated in response to distinct stimuli [30] [31] [32] [33] . Moreover, human acute lymphoblastic leukemia CCRF-CEM cells were preincubated with specific caspase 3 inhibitor (z-DEVD-fmk) before treatment of artonin B, and the caspase 3 activity, apoptotic cells and cell viability were analyzed by spectrophotometry analysis, Hoechst 33258 staining and MTT assay, respectively. Results showed that pre-incubation of cells with z-DEVD-fmk effectively inhibited artonin B-induced caspase 3 activity, apoptotic cell formation and cell death. Our data reveled that artonin B-induced nuclear fragmentation may be an apoptotic event provoked along with endonuclease activation via a caspase protein [34, 35] . We also examined the possibility that caspase 3 was involved in the morphological changes in artonin B-treated cells by measuring the caspase 3 activity with or without its inhibitor, z-DEVD-fmk. Theses data demonstrated that artonin B activated caspase 3 activity and consequent cell death.
However, the development of effective chemopreventive approaches must take into consideration the selective and differential effects manifested by different bioactive substances. Target specific agents that are capable of inducing selective apoptosis of cancer cells, but are harmless to normal cells are receiving considerable attention in the fields of cancer prevention and therapy [36] . Artonin Binduced cell cytotoxicity on human leukemia CCRF-CEM cells, but not on normal cells. Therefore, artonin B is a candidate for development as a chemopreventive agent.
In summary, our results demonstrate that cell cytotoxicity induced by artonin B in human CCRF-CEM leukemia cells is possibly mediated through apoptotic cell formation, mitochondrial pathways, Bcl-2 family protein expression, and the activation of caspase 3. However, artonin A, artocarpanone, and artocammunols CE have no effect on the cell survival rate of human CCRF-CEM leukemia cells. By analyzing the structure, more effective compounds might be reconstructured and new strategies for cancer therapy can be explored.
